Drugs / Ganoderma lucidum
Ganoderma lucidum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04319874 | Sep 2020 → Sep 2022 | osteosarcoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00432484 Comparator | May 2005 → Dec 2006 | rheumatoid arthritis | Chinese University of Hong Kong | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ganoderma lucidum | “traditional Chinese medicine (TCM) combination of Ganoderma lucidum and San Miao San (SMS)” PMID 17907228 ↗ Oct 2007 |
| Modality | Traditional medicine (herbal / TCM) | “traditional Chinese medicine (TCM) combination of Ganoderma lucidum and San Miao San (SMS)” PMID 17907228 ↗ Oct 2007 |
| Route | Oral | “Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.” NCT00432484 ↗ |